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Abstract In recent years, targeted agents have changed the treatment landscape for
patients with advanced renal cell carcinoma (RCC), greatly improving treat-
ment outcomes. Several targeted agents are now licensed for the treatment of
metastatic RCC (mRCC), and a number of new agents are under inves-
tigation. Axitinib, a small molecule indazole derivative is an oral, potent
multitargeted tyrosine kinase receptor inhibitor, which selectively inhibits
vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 at sub-
nanomolar concentrations, in vitro. In various nonclinical models, axitinib
has demonstrated in vivo target modulation and antiangiogenesis. In
pharmacokinetic studies, axitinib administered orally with food at the pro-
posed regimen of 5mg twice daily continuous daily dosing, is rapidly
absorbed, reaching peak concentrations within 2–6 hours. Axitinib is me-
tabolized primarily in the liver via the cytochrome P450 (CYP) system with
less than 1% of the administered drug passing unchanged in the urine. The
pharmacokinetics of axitinib do not appear to be altered by coadministered
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chemotherapies, and antacids do not have a clinically significant effect. How-
ever, coadministration with CYP3A4 and 1A2 inducers is contraindicated. In
addition, proton pump inhibitors reduce the rate of axitinib absorption. In-
creased axitinib exposure is associated with higher efficacy indicated by de-
creased tumor perfusion and volume. In three phase II clinical trials in patients
with advancedRCCpreviously treatedwith cytokines, chemotherapy or targeted
agents, axitinib has demonstrated antitumor activity with a favorable non-
cumulative toxicity profile. In one study of Western patients with cytokine-
refractory mRCC, an objective response rate (ORR) of 44.2% (95% CI 30.5,
58.7) was achieved. The median time to progression was 15.7 months (95%CI
8.4, 23.4) and the median overall survival (OS) was 29.9 months (95%CI 20.3,
not estimable). In the second study of patients with sorafenib-refractory
mRCC, ORR was 22.6% (95% CI 12.9, 35.0). The median progression-free
survival (PFS) was 7.4 months (95% CI 6.7, 11.0) and a median OS of 13.6
months (95% CI 8.4, 18.8) was achieved. Results from the third study in
Japanese patients with cytokine-refractory mRCC reported an ORR of 55%
and median PFS of 12.9 months (95% CI 9.8, 15.6).
In the three studies, the most common adverse events reported were fatigue,
hypertension, hand-foot syndrome (HFS), and gastrointestinal toxicity, which
were generally manageable with standard medical intervention. Of note, the
incidence of HFS and proteinuria in the Japanese study was higher than that
reported in the Western study in cytokine-refractory mRCC patients.
An observed association between diastolic blood pressure ‡90mmHg and
increased efficacy suggests potential use as a prognostic biomarker. However,
this requires further investigation. Two randomized phase III clinical trials
are ongoing to determine the efficacy of axitinib in patients with mRCC in the
first- and second-line setting. These results will help to determine the place of
axitinib in the mRCC treatment algorithm.
1. Introduction
Renal cell carcinoma (RCC) is the most com-
mon form of kidney cancer. It is diagnosed in
more than 200 000 patients worldwide every year
and accounts for approximately 100 000 deaths
annually.[1,2] In the last half-century, the in-
cidence of RCC has increased; in the US alone,
there has been a 126% increase in incidence and a
36.5% increase in mortality since 1950, with a
corresponding increase in annual mortality, pos-
sibly due to the continuing development of ad-
vanced screening techniques.[3,4]
Most cases of RCC are of clear cell histology,
which is often associated with mutations of the
Von Hippel-Lindau (VHL) tumor suppressor
gene, resulting in an increased transcription of
several hypoxia-inducible genes including vas-
cular endothelial growth factor (VEGF), a potent
signaling molecule involved in inhibition of den-
dritic cell maturation, tumor cell apoptosis, and
promotion of tumor angiogenesis.[5-8] The in-
cidence of metastatic RCC (mRCC) is highest in
developed regions, such as the US and Europe.[9]
mRCC is highly resistant to conventional treat-
ments, with a 5-year survival rate with stage IV
disease (of which one-third of patients present with
at initial diagnosis) of just 0–10%.[9] Additionally,
recurrence develops in approximately 20–40% of
patients treated for a localized tumor.[9,10]
Until recently, standard treatment for mRCC
has consisted of immunotherapy with either
interleukin-2 (IL-2) or interferon-a (IFNa), both
of which are associated with overall response
rates (ORRs) of 5–20%, and significant clinical
toxicities.[11-15] In randomized controlled trials,
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IFNa has been associated with a median overall
survival (OS) of 12–19 months,[16-18] and high-
dose IL-2 can result in disease cure in 5–10% of
patients.[19] Additionally, treatment options were
scarce for those patients who progressed on cyto-
kine therapy.
In recent years, targeted agents have changed
the treatment landscape for patients with ad-
vanced RCC, greatly improving treatment out-
comes. Several targeted agents are now licensed
for the treatment of mRCC, including the multi-
targeted tyrosine kinase inhibitors sunitinib,
sorafenib and pazopanib; the mammalian target
inhibitor of rapamycin (mTOR) kinase inhibitors
temsirolimus and everolimus; and the VEGF
monoclonal antibody bevacizumab in combina-
tion with IFNa.[20-25]
ORRs of 26–46% have been reported with these
targeted agents in patients with mRCC.[20,23,25]
Median progression-free survival (PFS) of
6–11 months has been achieved in treatment-naı¨ve
patients,[20,22,23,25] and 5–6 months in previously
treated patients.[21,24] Targeted agents have also
been associated with a significantly increased
median OS of up to 18 months in previously
treated patients,[21,24] while in treatment-naı¨ve
patients, median OS greater than 2 years has been
attained with sunitinib.[26] Targeted agents have
also shown efficacy in previously untreated patients
with poor prognosis, with the mTOR inhibitor
temsirolimus improving median OS by 49%
compared with IFNa alone.[22]
A number of second-generation targeted ther-
apies are on the horizon, including axitinib, a
potent and selective inhibitor of VEGF receptor
tyrosine kinases (VEGF RTK)-1, -2, and -3 that
has shown substantial anticancer activity in
phase II trials in patients with RCC. This article
discusses the preclinical and clinical data for ax-
itinib for the management of RCC.
2. Mode of Action and Rationale
2.1 Vascular Endothelial Growth Factor
Receptor (VEGFR) Signaling Pathway
Among other factors, the VEGFR signaling
pathway plays a key role in the pathogenesis and
progression of several tumor types as a pivotal
mediator of tumor angiogenesis.[27,28] VEGFR-1,
-2, and -3 are expressed in vascular sprouts, al-
though VEGFR-3 is found primarily in the lym-
phatic system.[28-31] Indeed, signaling via the
VEGFR family plays a role in regulating all three
key tumor processes: growth, vascular angio-
genesis, and metastatic spread.[27] VEGFR-1 is
involved in angiogenesis and tumor growth;
VEGFR-2 is involved in endothelial cell prolifera-
tion, migration and survival, and angiogenesis; and
VEGFR-3 is involved in lymphangiogenesis.[28,30]
2.2 Axitinib Anti-VEGFR Activity
Axitinib, a small molecule indazole derivative,
is an oral, potent, and highly selective inhibitor of
VEGFR-1, -2, and -3. The structure-based drug
design of axitinib allows strategic optimization of
critical binding elements, with the tight fit of ax-
itinib into the ’deep pocket’ conformation of the
kinase domain of VEGFRs resulting in high po-
tency and selectivity (figure 1).[32]
In vitro, axitinib inhibits VEGFR-1, -2, and
-3 autophosphorylation at picomolar concentra-
tions, consistent with its potent and highly selective
activity against these receptors. Indeed, the half
maximal inhibitory concentration (IC50) for ax-
itinib is 10-fold lower for the VEGF family recep-
tors than for RTKs of other family receptors.[32]
The IC50 for axitinib is also lower than other
RTK inhibitors for most of the targets of interest











Fig. 1. Axitinib drug design. Reproduced from Hu-Lowe et al.,[32]
with permission.
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and other agents targeting VEGFRs -1, -2, and -3
in mRCC are illustrated in figure 2.[33,39-45] Addi-
tionally, studies carried out in vitro showed that
axitinib did not significantly inhibit other receptor
kinases that were tested, including colony-stim-
ulating factor (CSF)-1R, fms-like tyrosine kinase
(Flt)-3, fibroblast growth factor receptor (FGFR)-1,
ret proto-oncogene (RET), epidermal growth fac-
tor receptor (EGFR), and met proto-oncogene
encoding hepatocyte growth factor (c-Met).[32]
2.3 Axitinib Antitumor Activity
Axitinib has demonstrated in vivo target
modulation and antiangiogenesis in several non-
clinical models.[32] In xenograft tumor mouse
models across various tumor types, axitinib anti-
tumor activity was associated with marked re-
duction in tumor vascularization and blood flow,
and tumor shrinkage. These were achieved at a
range of plasma concentrations consistent with
its in vitro potency and were dose dependent.[32]
The Ctarget value (required in vivo pharmacologic
concentration) was determined to be ~0.5 nmol/L
(unbound), which in humans would be equivalent
to a Ctarget of ~100 nmol/L (total).
In a phase I study of axitinib in patients with
advanced solid tumors, the maximum tolerated
dose and recommended dose in humans was de-
termined to be 5mg twice daily on a continuous
daily dosing schedule.[46] Hypertension and sto-
matitis were the main dose-limiting toxicities seen
during the phase I study; these were mainly ob-
served with higher doses of axitinib. Other ad-




Axitinib is administered orally on a proposed
standard dosing regimen of 5mg twice daily with
titration as required, and is rapidly absorbed,
with peak plasma concentrations measurable
within 2–6 hours after dosing in the fed state.[46]
Axitinib exhibits linear pharmacokinetics at
doses of 2–10mg twice daily.[46] Peak plasma
concentrations are reached in 1–2 hours after
dosing in the fasted state, while plasma half-life
remains unchanged.[46] Axitinib exists in different
crystal forms. With crystal polymorph Form IV,
higher plasma levels were observed after over-
night fasting, but not with shorter fasting times
(e.g. fasting 1 or 2 hours before and after each
dose).[47] Findings for polymorph Form XLI are
awaited.
Axitinib primarily undergoes hepatic metabo-
lism via the cytochrome P450 (CYP) 3A4 isozyme,
Table I. IC50 for selected targeted agents. Reproduced from Bellmunt et al.,
[33] with permission
Target IC50 (nM)
sunitinib[34,35] sorafenib[35-37] pazopanib[35,38] axitinib[32]
VEGFR-1 2 NR 10 0.1a
VEGFR-2 10 90 30 0.2
VEGFR-3 17 20 47 0.1–0.3
PDGFR-b 8 57 84 1.6
EGFR 880 58 NR NR
c-KIT 10 68 74 1.7
FGF-1R 880 580 14 231
FLT-3 14 58 NR >1000
Raf-1 NR 6 NR NR
CSF-1R 100 NR NR 73
a Converted from value obtained in the presence of 2.3% bovine serum albumin.
c-KIT = v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CSF = colony-stimulating factor; EGFR =endothelial growth factor
receptor; FGF = fibroblast growth factor; FLT =FMS-like tyrosine kinase; IC50= concentration of a drug that is required to achieve 50%
inhibition of the enzyme in a biochemical assay;NR =not reported; PDGFR = platelet-derived growth factor; Raf = v-raf-1 murine leukemia viral
oncogene homolog 1; VEGFR = vascular endothelial growth factor receptor.
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with some additional metabolism occurring via
oxidation by CYP2C19 and CYP1A2 and glu-
curonidation via uridine diphosphate glucuronosyl-
transferase (UGT) 1A1.[46] The major circulating
axitinib metabolites, the glucuronide and the
sulfoxide, are not active. Less than 1% of the ad-
ministered drug appears as unchanged drug in
the urine.[46]
No changes in the pharmacokinetic profile of
axitinib or comparator agents were observed
when axitinib was administered in combination
with chemotherapies including paclitaxel, doce-
taxel, cisplatin, carboplatin, oxaliplatin, 5-fluoro-
uracil, irinotecan, and/or gemcitabine.[48-52]
As both CYP3A4 and 1A2 are known to be
inducible, coadministration of axitinib with agents
known to be potent inducers is contraindicated.
Data from a single patient in a phase I study
demonstrated an interaction between axitinib and
phenytoin, a potent inducer of several CYP450
isozymes.[46] In this patient, the area under the
concentration-time curve from 0 to 24 hours
(AUC24) and the peak plasma concentration
(Cmax) of axitinib were reduced by 10-fold, and
the patient subsequently experienced disease pro-
gression, despite earlier response to axitinib, which
ultimately led to their discontinuation from
treatment. As a result of this, concomitant use of
potent inducers of the CYP3A4 and CYP1A2
isozymes was subsequently excluded during ax-
itinib treatment. In a phase I two-way crossover
study of axitinib given with or without rifampicin
in Japanese and Caucasian healthy volunteers
(n = 40), rifampicin (a potent inducer of drug-
metabolizing enzymes including CYP3A4, CYP1A2,
andUGT1A1) decreased theAUC from time zero
extrapolated to infinity (AUC¥) and Cmax of ax-
itinib (geometric mean reduced to 79% and 71%,
respectively).[53] No differences in pharmacokinetics
were observed between Japanese and Caucasian
subjects.
Since axitinib is predominantly metabolized
by CYP3A4, concomitant use of potent in-
hibitors with axitinib is also excluded. Data from
a phase I two-way crossover study of axitinib
alone or coadministered with ketoconazole (a
potent CYP3A inhibitor) in healthy volunteers
(n = 32) demonstrated that concurrent adminis-
tration of ketoconazole increased axitinib plasma





















Sunitinib ABT-869 Pazopanib Sorafenib Vatalanib
PTK787
Vandetanib
Fig. 2. Relative potency of targeted agents in metastatic renal cell carcinoma (mRCC).[32,33,39-45] IC50 = concentration that produces 50%
inhibition; VEGFR = vascular endothelial growth factor receptor. Reproduced from Bellmunt et al.,[33] with permission.
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2- and 1.5-fold increases in the geometric mean
values, respectively.[54] In addition, Cmax oc-
curred 1.5 hours after dosing with axitinib alone
compared with 2.0 hours after coadministration
with ketoconazole.
Antacids do not have a clinically significant
effect on axitinib pharmacokinetics.[46] Coadmin-
istration with the proton pump inhibitor, rabe-
prazole, reduced the rate of axitinib absorption,
leading to a decrease in Cmax, but had only mar-
ginal impact on AUC.[46]
3.2 Pharmacodynamics
In a study measuring the exposure-response re-
lationship of axitinib in patients with advanced solid
tumors, a >50% decrease in the volume transfer
coefficient (Ktrans) and initial area under the curve
was demonstrated by day 2 of therapy, and per-
sisted through week 4 of treatment (figure 3).[55] A
linear correlation suggested that increased axitinib
exposure is associated with higher efficacy, as in-
dicated by decreased tumor perfusion and volume.
4. Phase II Clinical Study Results
Axitinib has been studied in three phase II,
single-arm, multicenter, clinical trials investigat-
ing its efficacy, safety and pharmacodynamics in
patients with mRCC (table II).[56,57]
4.1 Efficacy
In the first study, conducted in 52 patients with
cytokine-refractory mRCC, patients received
axitinib (administered as 5mg twice daily) in the
fasted state in 28-day treatment cycles until dis-
ease progression or unacceptable toxicity.[56,58]

























Fig. 3. Quantitative representation of tumor initial area under the curve (IAUC) values mapped over the tumor region Ktrans, volume transfer
constant. Reproduced from Liu et al.,[55] with permission.
Table II. Summary of efficacy findings in key phase II studies [n (%)]




Objective response rate 23 (44) 14 (23)
complete response 2 (4) NR




Disease progression 4 (8) 25 (40)
Missing data 3 (6) 12 (19)
PFS (mo) 13.7 7.4
OS (mo) 29.9 13.6
OS =overall survival; NR = not reported; PFS = progression-free
survival.
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44.2% (23 patients; 95% CI 30.5, 58.7), as indicated
by two complete responses (4%) and 21 partial re-
sponses (PR; 40%) based on the Response Eval-
uation Criteria In Solid Tumors (RECIST).[59]
Additionally, 22 patients (42%) showed stable
disease (SD) lasting for longer than 8 weeks, in-
cluding 13 (25%) patients with SD for at least
24 weeks. The median duration of response was
23.0 months. The median time to progression was
15.7months (95%CI 8.4, 23.4), and themedianOS
was 29.9 months (95% CI 20.3, not estimable).
Maximum percentage decrease in target lesion size,
based on RECIST is shown in figure 4a.
The second phase II study evaluated axitinib
in 62 patients with advanced and refractory RCC
who had not responded to sorafenib-based ther-
apy.[57] In this study, prior therapies were not
limited to sorafenib, but could also include cyto-
toxic therapies, cytokines and other targeted
therapies such as sunitinib, bevacizumab, and
temsirolimus. PR was observed in 14 patients






















































Fig. 4. Tumor responses from phase II trials of axitinib in patients with metastatic renal cell carcinoma (mRCC). Each bar represents
one patient. Maximum percentage reduction in tumor size of target lesions by Response Evaluation Criteria In Solid Tumors (RECIST)
[-100%= complete response; -30%= partial response; n =48]. Reproduced from (a) Rini et al.[57] and (b) Rixe et al.,[56] with permission
bid = twice daily; CR = complete response; PR = partial response.
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in 11 patients (18%), and progressive disease in
25 patients (40%). Some degree of tumor shrink-
age was seen in 40 of 50 patients (80.0%) for
whom post-baseline data were available.
In this study, tumor responses were observed
within the group of patients who dose-titrated to
>5mg twice daily (7/33; 21%), as well as in
patients who remained on 5mg twice daily or
who were dose-modified to <5mg twice daily
(7/29; 24%). Maximum percentage reduction in
target lesions (by RECIST) during treatment
with axitinib based on dose titration is illustrated
in figure 4b. These results suggest that axitinib
dose titration (i.e. axitinib given at a higher dose
[above its standard starting dose]), may improve
the response to treatment in some patients. This is
being investigated in an ongoing randomized,
double-blind, phase II study of axitinib with or
without dose titration in patients with mRCC.[60]
After a median follow-up of 22.7 months (95%
CI 6.7, 11.0), the median PFS was 7.4 months
(95%CI 6.7, 11.0), andmedianOSwas 13.6months
(95% CI 8.4, 18.8).
In the third phase II study in Japanese patients
with mRCC refractory to previous cytokine-based
treatment, patients (n= 64) received continuous dos-
ing of axitinib (starting dose: 5mg twice daily).[58]
An ORR of 55% was reported in this study and
median PFS was 12.9 months (95% CI 9.8, 15.6).
4.2 Safety and Tolerability
For single-agent axitinib, the most common
AEs reported are hypertension, fatigue, and
gastrointestinal toxicity (table III).[56,57] These
AEs are an expected class effect due to the known
mechanism of action of the drug. The majority of
AEs are manageable with dose modification and
supportive care; hypertension is generally easily
managedwith standard antihypertensive drugs.[56,57]
In the three phase II studies in renal carcino-
ma, no unexpected AEs occurred. In the Western
Table III. Common adverse events reported in phase II clinical trials[56,57]
Adverse event Cytokine refractory (n= 52)[56] Sorafenib refractory (n= 62)[57]
all grades [n (%)] grade 3/4 [n (%)] all grades [n (%)] grade 3/4 [n (%)]
Diarrhea 31 (60) 5 (10) 38 (61) 9 (15)
Hypertension 30 (58) 8 (15) 28 (45) 10 (16)
Fatigue 27 (52) 4 (8) 48 (77) 10 (16)
Nausea 23 (44) 0 27 (44) 4 (7)
Hoarseness 19 (37) 0 NR NR
Dyspnea NR NR 24 (39) 9 (15)
Dysphonia NR NR 23 (37) 0
Hand-foot syndrome NR NR 22 (36) 10 (16)
Anorexia 18 (35) 1 (2) 30 (48) 0
Mucosal inflammation NR NR 21 (34) 1 (2)
Dry skin 17 (33) 0 NR NR
Weight loss 14 (27) 0 19 (31) 3 (5)
Dyspepsia 12 (23) 0 NR NR
Vomiting 11 (21) 0 20 (32) 3 (5)
Cough NR NR 18 (29) 0
Headache NR NR 18 (29) 1 (2)
Arthralgia NR NR 17 (27) 2 (3)
Constipation NR NR 16 (26) 0
Dysgeusia NR NR 14 (23) 0
Abdominal pain NR NR 13 (21) 7 (11)
Pain in extremity NR NR 13 (21) 2 (3)
NR= not reported.
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trial of cytokine-refractory patients, the most
common all-causality treatment-related AEs in-
cluded diarrhea (60%), hypertension (58%), and
fatigue (52%).[56] The most common grade 3–4 AEs
were hypertension (15%), diarrhea (10%), and
fatigue (8%), and no grade 3–4 hematologic tox-
icities were noted. Only four patients reported
treatment-related proteinuria, all of which were
grade 1–2. Of the 52 patients enrolled, ten patients
discontinued due to treatment-related AEs.[56]
In sorafenib-refractory patients, the most com-
mon all-causality AEs were fatigue (77%), diarrhea
(61%), anorexia (48%), and hypertension (45%).[57]
All-causality grade 3–4 AEs included hand-foot
syndrome (HFS; 16.1%), fatigue (16.1%), hyper-
tension (16.1%), dyspnea (14.5%), diarrhea (14.5%),
dehydration (8.1%), and hypotension (6.5%). Of
62 patients enrolled, treatment was discontinued
in 22 patients due to AEs (of these, 12 were at-
tributed to study treatment).[57]
Common treatment-related AEs reported in
the Japanese trial of cytokine-refractory patients
were HFS (73%), hypertension (66%), diarrhea
(66%), and hoarseness (53%). In all, 18 patients de-
veloped proteinuria ‡2g/24 hours during treatment
and required dose reduction or treatment inter-
ruption/discontinuation.[58] Of note, the incidences
of HFS and proteinuria in the Japanese study
were higher than those reported in the Western
study in cytokine-refractory mRCC patients.
These phase II data indicate that the con-
tinuous administration and the constant dose
of axitinib appear to have acceptable tolerability
and are compatible with long-term administra-
tion. Certainly, in the Western study in cyto-
kine-refractory mRCC, patients have received
axitinib for more than 3 years with no cumulative
toxicity.[56]
4.3 Diastolic Blood Pressure and
Clinical Efficacy
An interesting association between diastolic
blood pressure (DBP) and clinical efficacy ap-
pears to exist with axitinib therapy. Hypertension
is a commonly observed event during treatment
with axitinib and other VEGF signal inhibitors,
and is generally manageable with standard anti-
hypertensive agents. In a retrospective analysis of
axitinib treatment across multiple tumor types,
the occurrence of DBP ‡90mmHg was associated
with increased OS.[61]
A pooled analysis of the two axitinib phase II
mRCC studies (n = 114) explored the relationship
between pharmacokinetics, DBP, and clinical
efficacy.[61] Response was evaluated based on
RECIST-defined ORR, OS, and changes in tumor
size (the sum of lesion diameter; SLD). DBP and
mean steady-state AUC during axitinib treat-
ment were used as predictors of clinical efficacy in
mRCC patients using logistic regression.
Using this methodology, DBP ‡90mmHg and
AUC appear to be independent predictors of clin-
ical efficacy, with an improved clinical response (as
indicated by a reduction in SLD) associated with
increasing axitinib plasma exposure (AUC).
There was an increased probability (p < 0.05)
of achieving a PR with increasing AUC, with a
47% and 22% increase in the probability of achiev-
ing a PR for every 100 ng/h/mL increase in AUC
for cytokine-refractory and sorafenib-refractory
patients, respectively. Additionally, improved clini-
cal response was associated with greater changes
in DBP. Logistic regression analysis showed that
the probability of experiencing a PR increased
with greater maximum DBP (p < 0.05), and pa-
tients had an 86% increase in the probability of
achieving a PR for every 10mmHg increase in
DBP (p < 0.05; figure 5).[62]
OS was also longer in patients with at least one
DBP measurement ‡90mmHg during axitinib
therapy (p < 0.05), with a median OS of 130 weeks
for patients with DBP ‡90mmHg compared with
just 42 weeks for patients without DBP ‡90mmHg.
Interestingly, increases in AUC were not highly
correlated with changes in DBP.
Logistic regression and Kaplan-Meier analy-
ses showed that increased axitinib exposure and
DBP ‡90mmHg were independently associated
with several measures of clinical improvement,
including longer OS, greater probability of a PR,
and greater reductions in SLD.
In the Japanese phase II study,[58] patients with
at least one recorded DBP reading ‡90mmHg
during the first 28 days of treatment had signif-
icantly longer PFS compared with those without
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a DBP reading ‡90mmHg (median PFS, 14.6 vs
9.8 months; p = 0.02).
These data suggest that in patients with mRCC,
the occurrence of DBP ‡90mmHg during axitinib
treatment is not merely a reflection of higher
axitinib drug levels and, therefore, may be of
clinical interest and worthy of investigation as a
potential prognostic biomarker.
5. Ongoing Clinical Studies
Clinical investigation of axitinib is ongoing in
one phase II study[60,63] and two large-scale phase III
trials in patients with mRCC.[64,65]
5.1 Ongoing Phase II Clinical Study:
The AGILE 1046 Trial
TheAGILE 1046 trial is a prospective, random-
ized trial to evaluate (i) the efficacy of axitinib
treatment with or without dose titration in treat-
ment-naı¨ve mRCC patients; (ii) axitinib-related
changes in blood pressure (BP) using 24-hour am-
bulatory BP monitoring and telemedicine in a sub-
set of patients; and (iii) axitinib pharmacokinetics
over 6 hours, time-matched with BP measurements
prior to each pharmacokinetic sample.[63]
Patients will be randomized 1 : 1 to receive
axitinib 5mg twice daily plus dose titration with
axitinib (ArmA) or placebo (ArmB).Only the dose
titration portion will be blinded. Patients not
meeting randomization (dose-titration) criteria will
continue receiving axitinib without dose titration in
a separate, non-randomized arm (Arm C).[60,63]
The primary endpoint is ORR, and secondary
endpoints include PFS, OS, duration of response,
safety, pharmacokinetics, BP, and translational
medicine assessments.[60,63] Estimated enrollment
is 200 and the trial is currently recruiting partic-
ipants with an estimated enrollment period of
2 years.[63]
5.2 Ongoing Phase III Clinical Studies
5.2.1 The AGILE 1032 Trial
The AGILE 1032 trial is a global, phase III,
randomized, open-label study that will compare
the efficacy and safety of second-line axitinib
5mg twice daily or sorafenib 400mg twice daily
(both with continuous dosing) therapy in 723 pa-
tients with mRCC refractory to one prior first-
line therapy.[64] The primary endpoint is PFS,
with secondary endpoints including OS, response
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Fig. 5. Probability of a partial response with maximum diastolic blood pressure (DBP). Reproduced from Rixe et al.,[62] with permission.
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and specific renal symptoms and health status
measures. This 3-year trial has completed accrual
as of April 2010 and is expected to report out
in 2011.
5.2.2 The AGILE 1051 Trial
The second trial is a randomized, open-label,
phase III study (AGILE 1051 trial) evaluating
first- and second-line axitinib 5mg twice daily
versus sorafenib 400mg twice daily (again, both
with continuous dosing) in Asian and non-Asian
patients with mRCC who have either received no
prior systemic first-line therapy or have pro-
gressed after one prior systemic first-line regimen
for metastatic disease containing sunitinib, cyto-
kines, or both.[65] The primary and secondary
endpoints are the same as for the AGILE 1032
trial. At the time of writing, trial 1051 is still
recruiting, and has an estimated enrollment of
447 patients. A schema for this trial is shown in
figure 6.
6. Conclusions and Outlook
Axitinib is a potent and selective inhibitor of
VEGFR-1, -2, and -3, delivered orally, with a
convenient schedule of administration. Axitinib
has been shown to reduce vascular permeability,
tumor vascularization and tumor volume, and
has demonstrated antitumor activity as a single
agent in patients with cytokine- and/or sorafenib-
refractory mRCC. The activity range of axitinib
is the highest when compared with other active
drugs currently approved for use in mRCC, and
raises high expectations. Axitinib also has a fa-
vorable and non-cumulative tolerability profile
associated with manageable AEs, which are gen-
erally mild to moderate in severity. Potential as-
sociations between the efficacy of axitinib and
DBP are currently under evaluation, with prom-
ising preliminary results. The place of axitinib
in the oncologist’s armamentarium and the fu-
ture role of the drug in the treatment algorithm
for mRCC will be further elucidated in the two
ongoing, large-scale, phase III studies in this
disease.
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Secondary endpoints: OS, response rate, safety and tolerability, duration of
response, kidney specific symptoms and health status
• Stratification (first line):
       − ECOG PS (0 vs 1)
• Stratification (second line):
       − ECOG PS (0 vs 1)





Fig. 6. Study schema for AGILE 1051.[65] bid = twice daily; ECOG PS =Eastern Cooperative Oncology Group Performance Status;
mRCC =metastatic renal cell carcinoma; OS =overall survival; PFS = progression-free survival; RECIST =Response Evaluation Criteria In
Solid Tumors.
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